Key result
Metformin attenuated the increase in cardiorespiratory fitness following a 12-week exercise program in type 2 diabetes patients compared to those not on metformin.
Why the study?
Diabetes medications are often used alongside fitness promotion, but clinical data regarding potential synergistic interactions between exercise training and newer agents like SGLT2 inhibitors and incretin agonists on cardiorespiratory fitness remain preliminary.
Do diabetes medications (metformin, SGLT2 inhibitors, GLP-1 agonists) interact with physical fitness to improve cardiorespiratory fitness and cardiovascular outcomes in patients with type 2 diabetes?
Do diabetes medications (metformin, SGLT2 inhibitors, GLP-1 agonists) interact with physical fitness to improve cardiorespiratory fitness and cardiovascular outcomes in patients with type 2 diabetes?
While physical fitness is a cornerstone of diabetes management, concurrent use of medications like metformin may attenuate fitness gains, highlighting the need to better understand the interaction between newer diabetes agents and exercise to optimize cardiovascular benefits.
Answers are grounded in this paper and cite their sources.
Affirms exercise benefits in diabetes management; leaves open optimal regimens for highest-risk subgroups.
A plethora of diabetes studies and established clinical guidelines show the strong salutary benefit of aerobic, resistance, and/or combination exercise for improved glycemic and cardiovascular outcomes. Promotion of physical fitness is a cornerstone approach to improved diabetes management especially since subjects with diabetes have reduced baseline aerobic exercise capacity (i.e., reduced cardiorespiratory fitness) with associated increased risk for premature all-cause and cardiovascular mortality. Since medications are often used in conjunction with fitness promotion this can result in complex interaction between management modalities. More recently, newer options such as glucose transporter-2 inhibitors and incretin agonists have shown to improve cardiovascular disease (CVD) outcomes in cardiovascular outcomes trials. Indeed, both classes of agents have experimentally the potential to synergize with exercise training but clinical data vis-à-vis cardiorespiratory fitness is still preliminary. Review of the interaction of exercise and metformin shows no improvement in cardiorespiratory fitness. The use of glucose transporter-2 inhibitors may improve fitness performance in those with diabetes and heart failure. Although incretin agonists have physiological effects on the vasculature and heart, they lack similar clinical supportive data.
No takes yet. Share an insight, caveat, or question.
Eric Nylén (2022) conducted a review in Type 2 diabetes (n=147). Metformin vs. Not on metformin was evaluated on Increase in post-exercise cardiorespiratory fitness (peak metabolic equivalents) (p=<0.005). Metformin attenuated the increase in cardiorespiratory fitness following a 12-week exercise program in type 2 diabetes patients compared to those not on metformin.
Synapse has enriched 10 related papers. Consider them for comparative context: